

Keep out of reach of children
FOR ANIMAL TREATMENT ONLY

INCURIN[®]

ACTIVE CONSTITUENT: OESTRIOL, 1mg/TABLET

Treatment of hormone-responsive urinary incontinence due to sphincter mechanism incompetence in female dogs.

30 Tablets

Read the entire label and leaflet before use.

HANDLING PRECAUTIONS Danger may damage fertility or the unborn child from repeated oral exposure. Wash hands after use.

FIRST AID If exposed or concerned, get medical advice. For advice contact the National Poisons Centre 0800 POISON (0800 764 766) or a doctor.

DISPOSAL Dispose of any unused product and empty containers by burying in an approved landfill.

See Safety Data Sheet for further information. www.intervet.co.nz.

PRESENTATION

Small white to almost white round flat tablets packed in push through strips of 30. Each tablet contains oestriol (1mg).

PROPERTIES

Oestriol is a short-acting natural oestrogen. It has a beneficial effect on urinary incontinence in female dogs. On oral administration a steady state is reached after the second day of treatment and no accumulation occurs after multiple dosing.

INDICATIONS

Incurin is indicated for the treatment of urinary incontinence due to sphincter mechanism incompetence in ovariectomised or ovariohysterectomised female dogs.

DOSAGE AND ADMINISTRATION

Incurin is intended for once daily oral administration. There is no relationship between the size of the dog and the dose required, so a fixed mg/kg dose rate is not feasible.

Effectiveness is defined as no signs of incontinence for 7 consecutive days. An improvement will usually be noticed within a few days. However, adjustment of the initial dose will often be necessary, so at least 7 days should be allowed before judging the full effect of a certain dose rate.

The following dosing schedule is advised:

Initial dose: 1 tablet (1mg) per day for 7-14 days.

(a) If treatment with 1mg daily is effective, try to reduce the dose to the minimum possible with 7 days treatment as follows:

½ tablet/day, then

½ tablet on alternate days

If treatment is ineffective at the lower doses, titrate back to the next lowest dose.

(b) If treatment with 1mg daily is ineffective, increase the dose to 2mg daily for 7 days. (Maximum dose should not exceed 2mg/day). If effective, try reducing dose to 2mg on alternate days. However, if treatment with 2mg/day is ineffective, reassess case to confirm diagnosis, then consider supplementary therapy.

Treatment will continue for the remainder of the life of the dog.

CONTRAINDICATIONS, WARNINGS,

The use of Incurin is contraindicated during pregnancy and in animals younger than one year.

SIDE EFFECTS

Mild oestrogenic effects such as swollen vulva, swollen teats have been observed at the high dose of 2mg. These effects are reversible after lowering the dose. Occasionally nausea is observed. Because of its short-acting oestrogenic properties, Incurin does not induce bone marrow suppression in the dog.

STORAGE

Store at room temperature (15-25°C).

Prescription Animal Remedy **(P.A.R)** Class I For use only under the authority or prescription of a veterinarian.

Registered pursuant to the ACVM Act 1997, No. A8094. See www.nzfsa.govt.nz/acvm/ for registration conditions.

Registered to:
Schering-Plough Animal Health Ltd
Upper Hutt, NEW ZEALAND.
Phone: 0800 800 543